Reprocell signs microbiome research agreement with IFF

25-Apr-2022

The objectives of the study are to characterise the microbiome profile of this diverse cohort of healthy individuals from various sample types and to isolate microbial strains

Clinical research organisation Reprocell and IFF have entered into a clinical services agreement through which Reprocell will provide various types of samples for a study entitled: "Isolation and Characterization of Multiple Microbial Species from Diverse Healthy Adults (IsoMic)".

Participants in the study will include donors of various ethnicities, limited to a maximum of 10 from each of five ethnic group. In this study Reprocell will first screen the donors and select the healthy donors that meet the study criteria such as BMI, healthy dietary intake profile, and between 18 to 50 years of age. Required samples from the donors meeting the criteria will be collected and provided to the scientists at IFF for microbiome analysis.

The objectives of the study are to characterise the microbiome profile of this diverse cohort of healthy individuals from various sample types and to isolate microbial strains for possible future development as probiotic products.

Sign up for your free email newsletter

"This study will help us strengthen our capabilities in microbiome research and our understanding of a healthy human microbiome profile," said Ritesh Kumar, PhD, Research Investigator, IFF. "Reprocell is pleased to be participating in this exciting prospective collection for IFF under our strict IRB and informed consent processes," said Rama Modali, CEO, Reprocell.

Companies